Stereotaxis (STXS) Stock Price
Stereotaxis Price
Revenue has compounded at 0.9% per year over the past 19 years to 32.38 M USD. Stereotaxis's net margin stands at -66.8%, down from -30.6% several years earlier. Analysts set a median price target of 3.50 USD, implying 209.7% above the current price. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus.
Stereotaxis stock price
Stereotaxis business model & stock analysis
Frequently asked questions about Stereotaxis
Stereotaxis Inc is a leading company in the field of medical technology. The business model of Stereotaxis Inc revolves around providing innovative robotic systems for use in hospitals and medical facilities. These systems assist healthcare professionals in performing minimally invasive procedures, especially in the field of electrophysiology. By combining advanced robotics and precise imaging, Stereotaxis Inc enables physicians to navigate catheters and devices with enhanced accuracy and control. This ultimately improves patient outcomes and reduces the risks associated with traditional surgical methods. With a focus on medical innovation, Stereotaxis Inc continues to revolutionize the healthcare industry through its state-of-the-art robotic technologies.
Stereotaxis Inc is primarily active in the healthcare industry.
The main competitors of Stereotaxis Inc in the market include XYZ Corporation, ABC Corporation, and LMN Corporation.
Stereotaxis Inc is a leading healthcare technology company specializing in robotic surgical systems. Founded in 1990, Stereotaxis has transformed the field of electrophysiology by developing and commercializing innovative robotic platforms. The company's proprietary technology enables physicians to perform precise and minimally invasive procedures, improving patient outcomes. Stereotaxis' versatile robotic systems, including the Niobe® Magnetic Navigation System, have gained recognition for their exceptional precision and safety. With a strong commitment to technological advancements, Stereotaxis Inc continues to revolutionize the medical industry, providing healthcare professionals with cutting-edge tools for improved patient care.
Stereotaxis Inc has achieved several significant milestones since its inception. Notably, the company revolutionized the field of robotic navigation in healthcare by developing the world's first robotic magnetic navigation system. This pioneering technology, known as the Niobe system, enables precise control and navigation of catheters during minimally invasive procedures. Stereotaxis Inc has also successfully expanded its global presence, with installations of the Niobe system in leading hospitals worldwide. Additionally, the company has consistently demonstrated its commitment to innovation, regularly enhancing its platform with advanced features and software updates. These accomplishments have solidified Stereotaxis Inc as a leading player in the field of robotic-assisted healthcare navigation.
Stereotaxis Inc is primarily present in the United States.
Stereotaxis Inc represents values of innovation, precision, and patient-centered care. This medical technology company is committed to revolutionizing the field of surgical robotics, particularly in the area of cardiac care. Their corporate philosophy focuses on enhancing clinical outcomes, reducing procedure time, and improving patient safety through their advanced robotic navigation systems. Stereotaxis Inc aims to provide healthcare professionals with cutting-edge tools that enable minimally invasive procedures and precise, personalized treatments. By harnessing the power of technology and research, Stereotaxis Inc strives to elevate the standard of care for patients worldwide.
Analysts currently set an average price target of 3.50 USD for the Stereotaxis stock (median: 3.50 USD), implying +209.7 % versus the latest price. The consensus is based on 9 analyst ratings.
9 analysts currently rate the Stereotaxis stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Stereotaxis to generate revenue of 34.33 M USD and earnings per share of -0.18 USD.
Converted at the current exchange rate, the Stereotaxis share trades at 1.01 EUR (1.13 USD).
The Stereotaxis share (STXS) is listed on 3 stock exchanges, including: Frankfurt (RJR1.F), München (RJR1.MU).
The company Stereotaxis Inc has developed an innovative business model that revolutionizes the diagnosis and treatment of heart diseases. The company is a leader in the development of technologies for magnetic catheter treatment, a minimally invasive method for treating heart diseases. Stereotaxis is a global company based in the USA and operates in Europe, Asia, and Australia. The company develops and produces magnetic catheter systems used by cardiologists to treat heart diseases in patients. Stereotaxis' magnetic catheter technology enables precise navigation through the body using an electric magnetic field. The application can be done minimally invasively without surgery. The technology consists of a catheter controlled by a computer. The doctor navigates the catheter using a magnetic field and visualizes the position of the catheter on a screen. Stereotaxis' flagship product is the "Niobe" magnetic catheter system. The system consists of various components, including a computer, a console, a control unit, sensors, catheters, and accessories. The Niobe system has been approved by the US Food and Drug Administration (FDA) and is used by cardiologists worldwide. In addition to selling magnetic catheter systems for the treatment of heart diseases, Stereotaxis also offers services such as the management of magnetic catheter labs. The company provides installation and training services for doctors and medical personnel to ensure effective use of the system. Stereotaxis is not only a hardware provider but also a provider of imaging and diagnostic software. Their "Odyssey" system provides a comprehensive platform for processing patient data and integrating medical devices. Odyssey enables better real-time collaboration among medical personnel and provides opportunities for data analysis. Stereotaxis operates a product focused on data collection and analysis, "Vdrive". Vdrive is a wireless and user-friendly instrument for documenting and recording information during invasive cardiology procedures by medical personnel. It enables the management of patient and procedure data, workflow optimization, and quality management. In addition, Stereotaxis offers a comprehensive fleet of service technicians. Operating globally, it provides 24/7 maintenance and support for the technical equipment in cardiology laboratories. Stereotaxis also has a dedicated marketing department for its customers, which organizes symposia, workshops, and conferences among other activities. Overall, Stereotaxis offers a comprehensive range of products and services for magnetic catheter treatment. With their latest innovations in mixed reality technology and zebra MRI system, the company will continue to conduct groundbreaking research and push the boundaries of medical science.
The expected revenue of Stereotaxis is 34.33 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Stereotaxis is -17.60 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Stereotaxis is currently -6.16. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Stereotaxis stock.
The price-to-sales ratio (P/S) of Stereotaxis is currently 3.16. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Stereotaxis stock.
The Eulerpool Quality Score for Stereotaxis is 2/10.
The ISIN of Stereotaxis is US85916J4094. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Stereotaxis is A1J09L. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Stereotaxis is STXS. The ticker symbol is used to trade Stereotaxis shares on the stock exchange.
Stereotaxis stock
Stereotaxis Peer Group
Stereotaxis Ticker
Stereotaxis FIGI
All fundamentals and in-depth analysis of Stereotaxis
Our stock analysis for Stereotaxis stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Stereotaxis. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.